MX2009008914A - Anticuerpos y composiciones farmaceuticas que contienen los mismos, utiles para inhibir la actividad de metaloproteinas. - Google Patents

Anticuerpos y composiciones farmaceuticas que contienen los mismos, utiles para inhibir la actividad de metaloproteinas.

Info

Publication number
MX2009008914A
MX2009008914A MX2009008914A MX2009008914A MX2009008914A MX 2009008914 A MX2009008914 A MX 2009008914A MX 2009008914 A MX2009008914 A MX 2009008914A MX 2009008914 A MX2009008914 A MX 2009008914A MX 2009008914 A MX2009008914 A MX 2009008914A
Authority
MX
Mexico
Prior art keywords
metalloproteins
antibodies
pharmaceutical compositions
compositions containing
inhibiting activity
Prior art date
Application number
MX2009008914A
Other languages
English (en)
Inventor
Irit Sagi
Tamar Danon
Netta Sela
Abraham Shanzer
Rina Arad-Yellin
Raghavendra Kikkeri
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Publication of MX2009008914A publication Critical patent/MX2009008914A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/61—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms not forming part of a nitro radical, attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F3/00—Compounds containing elements of Groups 2 or 12 of the Periodic System
    • C07F3/06—Zinc compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

La presente invención se relaciona a un compuesto que tiene la Fórmula general: (I); en donde: m y n son cada uno independientemente un número entero de 1 a 6; X1-X3 y Y1-Y3 son cada uno independientemente O o S; R1-R3 son cada uno independientemente seleccionados del grupo que consiste de hidrógeno, alquilo y cicloalquilo; y R es (CH2)x-C(-O)NR´-(CH2)y-N R´R´´ mientras que: x y y son cada uno independientemente un número entero de 1 a 6; y R´ y R´´ son cada uno independientemente seleccionados del grupo que consiste de, hidrógeno, alquilo y cicloalquilo; y a un anticuerpo que comprende una región de reconocimiento de antígeno capaz de enlazar específicamente el compuesto anterior.
MX2009008914A 2007-02-23 2008-02-21 Anticuerpos y composiciones farmaceuticas que contienen los mismos, utiles para inhibir la actividad de metaloproteinas. MX2009008914A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90285407P 2007-02-23 2007-02-23
PCT/IL2008/000230 WO2008102359A1 (en) 2007-02-23 2008-02-21 Antibodies and pharmaceutical compositions containing same useful for inhibiting activity of metalloproteins

Publications (1)

Publication Number Publication Date
MX2009008914A true MX2009008914A (es) 2009-08-28

Family

ID=39534848

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009008914A MX2009008914A (es) 2007-02-23 2008-02-21 Anticuerpos y composiciones farmaceuticas que contienen los mismos, utiles para inhibir la actividad de metaloproteinas.

Country Status (11)

Country Link
US (5) US8324355B2 (es)
EP (1) EP2155691B1 (es)
JP (2) JP5513130B2 (es)
KR (1) KR20090113908A (es)
CN (1) CN101702906B (es)
BR (1) BRPI0807256A2 (es)
CA (1) CA2678304A1 (es)
IL (2) IL224120A (es)
MX (1) MX2009008914A (es)
RU (1) RU2503682C2 (es)
WO (1) WO2008102359A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20090113908A (ko) 2007-02-23 2009-11-02 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 금속단백질 활성 억제용 항체 및 이를 함유하는 약학적 조성물
JP2011506614A (ja) 2007-12-17 2011-03-03 ダイアックス コーポレーション Ｍｍｐ−１４結合タンパク質を含む、骨溶解性障害を処置するための組成物および方法
JP2011517320A (ja) * 2008-03-03 2011-06-02 ダイアックス コーポレーション メタロプロテアーゼ９結合タンパク質およびメタロプロテアーゼ２結合タンパク質
CA3026701C (en) * 2009-03-02 2023-04-18 Massachusetts Institute Of Technology Methods and products for in vivo enzyme profiling
AU2011210362B2 (en) * 2010-01-27 2015-09-10 Yeda Research And Development Co. Ltd. Antibodies that inhibit metalloproteins
CN104530238B (zh) 2010-08-27 2019-11-26 吉利德生物制剂公司 基质金属蛋白酶9的抗体
ES2688457T3 (es) 2010-10-28 2018-11-02 Yeda Research And Development Co. Ltd. Métodos de generación de anticuerpos contra metaloenzimas
WO2013059439A2 (en) 2011-10-21 2013-04-25 Dyax Corp. Combination therapy comprising an mmp-14 binding protein
US9732156B2 (en) 2012-02-29 2017-08-15 Gilead Biologics, Inc. Methods of treating rheumatoid arthritis using antibodies to matrix metalloproteinase 9
AU2015239145B2 (en) 2014-04-03 2019-07-11 Csl Behring Ag Nebulization of immunoglobulin
US11432305B2 (en) * 2014-05-19 2022-08-30 Qualcomm Incorporated Apparatus and method for synchronous multiplexing and multiple access for different latency targets utilizing thin control
US11019620B2 (en) 2014-05-19 2021-05-25 Qualcomm Incorporated Apparatus and method for inter-band pairing of carriers for time division duplex transmit- and receive-switching and its application to multiplexing of different transmission time intervals
EP2985296A1 (en) * 2014-08-13 2016-02-17 Calypso Biotech SA Antibodies specific for MMP9
WO2017176017A1 (en) * 2016-04-04 2017-10-12 Samsung Electronics Co., Ltd. Method and apparatus for transmitting and receiving feedback in wireless communication system
WO2018148595A1 (en) * 2017-02-10 2018-08-16 Washington University Antibodies to tip1 and methods of use thereof
US11926655B2 (en) 2017-07-18 2024-03-12 Daiichi Sankyo Company, Limited Active MMP9-binding peptide
EP3911753A1 (en) 2019-01-17 2021-11-24 Massachusetts Institute of Technology Sensors for detecting and imaging of cancer metastasis
IL264768A (en) 2019-02-10 2020-08-31 Sagi Irit ANTI-MATRIX METALLOPROTEINASE 7 (MMP-7) inhibitory antibody and its use
US11332546B2 (en) 2019-05-21 2022-05-17 The Regents Of The University Of California Protease inhibitory antibodies and methods of use thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4595700A (en) * 1984-12-21 1986-06-17 G. D. Searle & Co. Thiol based collagenase inhibitors
GB8827305D0 (en) 1988-11-23 1988-12-29 British Bio Technology Compounds
JP3348725B2 (ja) 1992-04-07 2002-11-20 ブリティッシュ バイオテック ファーマシューティカルズ リミテッド ヒドロキサム酸ベースのコラゲナーゼとサイトカイン阻害剤
GB9320660D0 (en) 1993-10-07 1993-11-24 British Bio Technology Inhibition of cytokine production
WO1995029892A1 (en) 1994-04-28 1995-11-09 The Du Pont Merck Pharmaceutical Company Hydroxamic acid and amino acid derivatives and their use as anti-arthritic agents
AU2361295A (en) 1994-04-28 1995-11-29 Merck & Co., Inc. N-carboxyalkyl derivatives as antidegenerative active agents
GB9416897D0 (en) 1994-08-20 1994-10-12 British Biotech Pharm Metalloproteinase inhibitors
ATE226936T1 (de) 1995-08-08 2002-11-15 Ono Pharmaceutical Co Hydroxamsäurederivate verwendbar zur hemmung von gelatinase
IL116126A0 (en) * 1995-11-24 1996-01-31 Yeda Res & Dev Process for the preparation of bacteriochlorophyllis some novel compounds of this type and pharmaceutical compositions comprising them
ATE225343T1 (de) 1995-12-20 2002-10-15 Hoffmann La Roche Matrix-metalloprotease inhibitoren
ATE262899T1 (de) 1996-01-02 2004-04-15 Aventis Pharma Inc Substituierte (aryl, heteroaryl, arylmethyl oder heteroarylmethyl) hydroxamisaeureverbindungen
KR20000022532A (ko) 1996-06-27 2000-04-25 오노 야꾸힝 고교 가부시키가이샤 아릴(설파이드, 설폭시드 및 설폰)유도체 및 이를 활성 성분으로 함유하는 약물
US6174915B1 (en) * 1997-03-25 2001-01-16 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
KR20010072089A (ko) * 1998-07-30 2001-07-31 로즈 암스트롱, 크리스틴 에이. 트러트웨인 매트릭스 메탈로프로테이나제 억제제로서 트리시클릭술폰아미드 및 그의 유도체
IL178921A0 (en) * 1998-12-24 2007-03-08 Yeda Res & Dev Caspase-8 interacting proteins
ATE517926T1 (de) * 2003-04-04 2011-08-15 Yeda Res & Dev Antikörper zur hemmung der aktivität von mmp-2 und mmp-9
KR20090113908A (ko) * 2007-02-23 2009-11-02 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 금속단백질 활성 억제용 항체 및 이를 함유하는 약학적 조성물
AU2011210362B2 (en) 2010-01-27 2015-09-10 Yeda Research And Development Co. Ltd. Antibodies that inhibit metalloproteins

Also Published As

Publication number Publication date
RU2503682C2 (ru) 2014-01-10
US20100233188A1 (en) 2010-09-16
US20130030158A1 (en) 2013-01-31
US20160257765A1 (en) 2016-09-08
AU2008218525A1 (en) 2008-08-28
US9902783B2 (en) 2018-02-27
KR20090113908A (ko) 2009-11-02
US20180134808A1 (en) 2018-05-17
IL224120A (en) 2016-05-31
EP2155691A1 (en) 2010-02-24
US9416195B2 (en) 2016-08-16
US8324355B2 (en) 2012-12-04
BRPI0807256A2 (pt) 2014-07-22
CN101702906B (zh) 2014-02-12
WO2008102359A1 (en) 2008-08-28
RU2009132006A (ru) 2011-02-27
US20130224225A1 (en) 2013-08-29
US8486653B2 (en) 2013-07-16
JP2010519289A (ja) 2010-06-03
CN101702906A (zh) 2010-05-05
JP5513130B2 (ja) 2014-06-04
JP2013241435A (ja) 2013-12-05
CA2678304A1 (en) 2008-08-28
WO2008102359A9 (en) 2009-05-22
JP5792231B2 (ja) 2015-10-07
EP2155691B1 (en) 2016-01-13
IL224121A (en) 2016-05-31

Similar Documents

Publication Publication Date Title
MX2009008914A (es) Anticuerpos y composiciones farmaceuticas que contienen los mismos, utiles para inhibir la actividad de metaloproteinas.
EA200800822A1 (ru) Конъюгаты гидроксиалкилкрахмала и действующего вещества, полученные химическим лигированием через тиазолидин
WO2006060424A3 (en) Inducible nitric oxide synthase dimerization inhibitors
ATE296797T1 (de) N-(aryl/heteroaryl/alkylacetyl) amino saüre amide,pharmazeutische zusammensetzungen damit, und methodenzur inhibierung beta-amyloid peptid freisetzung oder synthese
ATE427932T1 (de) 11beta-hsd1-inhibitoren
IL190333A (en) Process and intermediates for the synthesis of caspofungin
EA200870358A1 (ru) 2-(циклический амино) пиримидоновые производные в качестве ингибиторов tpk1
NO20084701L (no) Ny heterocyklisk forbindelse eller salt eller intermediat derav
EA200700699A1 (ru) Ингибиторы взаимодействия между mdm2 и p53
HK1111999A1 (en) Spiroketal derivative and use thereof as diabetic medicine
EA201171328A1 (ru) Производное замещенного изохинолина
ATE503746T1 (de) Neue imidazolidinderivate
JO2644B1 (en) Derivatives of N- (amino-aryl mixture) -H1- indole-2-carboxamide Synthesis and therapeutic use
MY149180A (en) Uracil compound having inhibitor activity on human deoxyuridine triphosphatase or salt thereof
BRPI0714885B8 (pt) compostos terapêuticos e seu uso
DE60123674D1 (de) Perylenpigmentzusammensetzungen
TW200716089A (en) BCRP/ABCG2 inhibitor
TW200714598A (en) Urea derivatives, methods for their manufacture, and uses therefor
WO2006103101A3 (en) MEANS FOR THE INHIBITION OF ANTI-β1-ADRENERGIC RECEPTOR ANTIBODIES
ES2199696A1 (es) Mezclas de estabilizantes
DE602004003948D1 (de) Herstellung von 2-18f-2-desoxy-d-glucose durch festphasensynthese
TW200616997A (en) The preparation method for 6-substituted-1-methyl-1h-benzoimidazol derivatives and their preparation imtermediates
MX2022007499A (es) Compuestos adhesivos fotoprotectores y usos de los mismos.
WO2004103967A3 (en) Thiocarbamate inhibitors of alpha-4 integrins
IL196085A0 (en) Cyclic amine compounds and pharmaceutical compositions containing the same

Legal Events

Date Code Title Description
FA Abandonment or withdrawal